Abstract
Background Despite increasing incidences of hypertension, recent trends in mortality and urgent dialysis following acute hypertension (AHT) remain undetermined.
Methods This retrospective observational cohort study evaluated 50,316 hospitalized AHT patients from 2010 to 2019, using an administrative claims database in Japan. We examined trends in incidence, urgent dialysis, mortality and its risk factors using logistic regression models. Using ICD-10 codes, AHT was categorized into five spectrums: malignant hypertension (MHT) (n = 1,792), hypertensive emergency (n = 17,907), hypertensive urgency (n = 1,562), hypertensive encephalopathy (n = 6,593), and hypertensive heart failure (HHF) (n = 22,462).
Results The median age of the patients was 76 years and 54.9% were female. The total AHT incidence was 70 cases per 100,000 admission year. The absolute death rate increased from 1.83% [95% confidence intervals (CI), 1.40–2.40] to 2.88% (95%CI, 2.42–3.41) [Cochran-Armitage trend test (CA), P < 0.0001]. Upward trends were observed in patients aged ≥80, with lean body mass index ≤18.4, and with HHF. Urgent dialysis rates increased from 1.52% (95%CI, 1.12–2.06) to 2.60% (2.17–3.1) (CA, P = 0.0071) in 48,235 patients, excluding maintenance dialysis patients. Older age, male, lean body mass, MHT, HHF, and underlying chronic kidney disease (CKD) correlated with higher mortality risk; greater hospital volume correlated with lower mortality risk; and MHT, HHF, diabetes mellitus, CKD, and scleroderma correlated with a higher risk of urgent dialysis.
Conclusions Mortality and urgent dialysis rates following AHT have increased. Aging, complex comorbidities, and HHF-type AHT contributed to the rising trend of mortality.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study was supported by the Health and Labour Sciences Research Grant (Grant No. Seisaku-Sitei-22AA2003 to KF) of the Japan Ministry of Health, Labour and Welfare.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This study was approved by the ethical committee of Tokyo Medical and Dental University (M2000-2224) and conducted in accordance with the Helsinki Declaration's ethical principles.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
The data underlying the results in this study are available from the DPC Research Institute, 4F Ginmatsu Building 1-14-11 Ginza, Chuo-ku, Tokyo 104-0061 (E-mail: info{at}dpcri.or.jp) for researchers who meet the criteria for access to confidential data.
